UC Berkeley scientists develop new COVID nasal spray that targets present, future virus mutations
https://abc7news.com/covid-19-uc-berkeley-nasal-spray-covid-treatment-protection-against/12113152/
………………
The newly developed nasal spray is designed to prevent infections even from mutations. And if someone already had COVID, a version dispensed from something like an asthma inhaler would decrease the severity of the symptoms. No refrigeration would be required so it has global ramifications.
UC Berkeley scientists are ready to take their new COVID preventive to the FDA to move forward with clinical trials in humans. If all goes as predicted, it could be available for use by fall of 2023.
其它研究机构，和公司也在开发鼻喷治疗新冠
Glenmark’s nitric oxide nasal spray (NONS), which it sells under the brand FabiSpray in India, reduces the viral load of Sars-CoV-2 in high-risk adult Covid-19 patients by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.
https://www.fiercepharma.com/drug-delivery/covid-19-nasal-spray-starts-clinical-development-u-k
